Trigriluzole - Biohaven Pharmaceutical

Drug Profile

Trigriluzole - Biohaven Pharmaceutical

Alternative Names: BHV-4157; FC 4157

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yale University
  • Developer Biohaven Pharmaceutical Holding Company; National Cancer Institute (USA); Rutgers Cancer Institute of New Jersey
  • Class Antineoplastics; Benzothiazoles; Small molecules
  • Mechanism of Action Glutamate modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinocerebellar degeneration
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours
  • Preclinical Obsessive-compulsive disorders
  • Discontinued Spinocerebellar degeneration

Most Recent Events

  • 30 Oct 2017 Biohaven Pharmaceutical Holding Company enters into a clinical collaboration agreement with the Rutgers Cancer Institute of New Jersey to evaluate trigriluzole in combination with PD-1 blocking antibodies in patients with inoperable, advanced or refractory cancers
  • 24 Oct 2017 US FDA issues "May Proceed Letter" to Biohaven Pharmaceutical Holding Company to conduct a phase II/III trial of trigriluzole in Obsessive-compulsive disorders (PO)
  • 02 Oct 2017 Discontinued - Phase-II/III for Spinocerebellar degeneration in USA following negative topline results (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top